TapewireFind a company

person · Reporting owner

Nandabalan Krishnan

Disclosed activity across 1 company

Tapewire entity
114566
SEC CIK
0001733387

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BioXcel Therapeutics, Inc.BTAI · Entity 8380Director · 10% ownerApril 06, 2023April 10, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BioXcel Therapeutics, Inc.

Report date April 06, 2023 · Filed April 10, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2023-04-06 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2023-04-06 · Exercise / conversion · Acquired 60,000 · Balance 60,000

Row 2 · 2023-04-06 · Sale · Disposed 60,000 · Balance 0

F1: The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.

F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2027-08-23Direct294,000 Reported balance After 2023-04-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2023-04-06 · Exercise / conversion · Disposed 60,000 · Balance 294,000

F4: The options are fully vested and exercisable.

Common StockSEC Table I · non-derivativeIndirectSee footnote8,546,750 Reported balance Holding disclosure · report date 2023-04-06 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 8,546,750

F3: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Holdings"). By virtue of the Reporting Person's relationship with BioXcel LLC and Holdings, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.

F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Holdings"). By virtue of the Reporting Person's relationship with BioXcel LLC and Holdings, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F4: The options are fully vested and exercisable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 06, 2023 Filed Apr 10, 2023 22:20 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionStock Options · Derivative 60,000 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001104659-23-043694 · tm2312272-1_4seq1.xml · derivative · entry 4

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 294,000

Underlying: Common Stock · 60,000 shares

Expires 2027-08-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The options are fully vested and exercisable.

Read SEC document
April 06, 2023 Filed Apr 10, 2023 22:20 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 60,000 $17.32 $1,039,200.00
Disclosure

SEC source: 0001104659-23-043694 · tm2312272-1_4seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022.

F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
April 06, 2023 Filed Apr 10, 2023 22:20 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionCommon Stock 60,000 $0.41 $24,600.00
Disclosure

SEC source: 0001104659-23-043694 · tm2312272-1_4seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 05, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionStock Options · Derivative 25,889 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · derivative · entry 9

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,000

Underlying: Common Stock · 25,889 shares

Expires 2027-08-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

Read SEC document
January 05, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 800 $22.93 $18,344.00
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 6

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.

F5 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.90 to $23.04. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 25,089 $22.32 $559,986.48
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 5

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 800

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.

F4 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.90 to $22.89. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
January 05, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionCommon Stock 25,889 $0.41 $10,614.49
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 4

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 04, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionStock Options · Derivative 34,111 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · derivative · entry 8

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,889

Underlying: Common Stock · 34,111 shares

Expires 2027-08-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The options are fully vested and exercisable.

Read SEC document
January 04, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 9,821 $22.21 $218,124.41
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 3

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.

F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.0367 to $22.42. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
January 04, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 24,290 $21.59 $524,421.10
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,821

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.

F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.03 to $22.0263. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
January 04, 2023 Filed Jan 7, 2023 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionCommon Stock 34,111 $0.41 $13,985.51
Disclosure

SEC source: 0001104659-23-001945 · tm232491-1_4seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,111

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 15, 2022 Filed Feb 14, 2023 21:44 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 291,097 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-021791 · tm236671-2_5seq1.xml · nonDerivative · entry 3

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F3 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's spouse receieved by gift shares of Parent representing a 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F3 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's spouse receieved by gift shares of Parent representing a 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
November 15, 2022 Filed Feb 14, 2023 21:44 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 291,097 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-021791 · tm236671-2_5seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F2 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
November 15, 2022 Filed Feb 14, 2023 21:44 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 145,549 $0.00 $0.00
Disclosure

SEC source: 0001104659-23-021791 · tm236671-2_5seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F1 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F1 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
November 11, 2022 Filed Nov 15, 2022 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionStock Options · Derivative 32,550 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · derivative · entry 7

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 414,000

Underlying: Common Stock · 32,550 shares

Expires 2027-08-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The options are fully vested and exercisable

Read SEC document
November 11, 2022 Filed Nov 15, 2022 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 32,550 $15.00 $488,250.00
Disclosure

SEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 4

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.

F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
November 11, 2022 Filed Nov 15, 2022 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionCommon Stock 32,550 $0.41 $13,345.50
Disclosure

SEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 3

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 10, 2022 Filed Nov 15, 2022 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionStock Options · Derivative 27,450 $0.00 Strike: $0.41 $0.00
Disclosure

SEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · derivative · entry 6

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 446,550

Underlying: Common Stock · 27,450 shares

Expires 2027-08-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The options are fully vested and exercisable

Read SEC document
November 10, 2022 Filed Nov 15, 2022 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 27,450 $15.00 $411,750.00
Disclosure

SEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.

F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Read SEC document
November 10, 2022 Filed Nov 15, 2022 01:00 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Exercise / conversionCommon Stock 27,450 $0.41 $11,254.50
Disclosure

SEC source: 0001104659-22-118836 · tm2230464-1_4seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 25, 2021 Filed Jun 29, 2021 21:23 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 SaleCommon Stock 473,250 $30.83 $14,589,492.98
Disclosure

SEC source: 0001104659-21-086946 · tm2119762-8_4seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,546,750

F1 · kind: On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.

F1 · price: On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.

F2 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F1 · ownership.nature: On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions.

F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F3 · ownership.nature: Does not include 1,000 shares of the Issuer's common stock inadvertently previously reported as indirectly beneficially owned by The Sunanda Family Trust. Such shares are no longer held by the Reporting Person following the gift disposition of such shares on December 1, 2020.

Read SEC document
April 06, 2021 Filed Feb 14, 2022 22:37 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 102,568 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 4

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F4 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F4 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
April 06, 2021 Filed Feb 14, 2022 22:37 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 130,659 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 3

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F3 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse receieved by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F3 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse receieved by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
April 06, 2021 Filed Feb 14, 2022 22:37 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 130,659 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F2 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
April 06, 2021 Filed Feb 14, 2022 22:37 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 102,568 $0.00 $0.00
Disclosure

SEC source: 0001104659-22-023281 · tm226624-1_5seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 8,546,750

F1 · shares: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F1 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
December 01, 2020 Filed Feb 16, 2021 22:28 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 185,150 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-024416 · tm216714-2_5seq1.xml · nonDerivative · entry 3

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,020,000

F2 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
December 01, 2020 Filed Feb 16, 2021 22:28 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 185,150 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-024416 · tm216714-2_5seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,020,000

F1 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F1 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
July 24, 2020 Filed Feb 16, 2021 22:28 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 80,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-024416 · tm216714-2_5seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
July 24, 2020 Filed Feb 16, 2021 22:26 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 OtherCommon Stock 80,000 $60.76 $4,860,800.00
Disclosure

SEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 4

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

F4 · kind: See footnote (2). These securities were acquired as the result of the distribution of the Issuer's common stock by Parent to the Reporting Person in return for the cancellation of a proportional number of shares owned in Parent owned by the Reporting Person.

Read SEC document
July 24, 2020 Filed Feb 16, 2021 22:26 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 OtherCommon Stock 160,000 $60.76 $9,721,600.00
Disclosure

SEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 3

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 9,020,000

F2 · kind: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder.

F3 · kind: By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F2 · balance_after: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder.

F3 · balance_after: By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder.

F3 · ownership.nature: By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
February 24, 2020 Filed May 13, 2020 23:21 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 Disposition to issuerCommon Stock 300,000 $30.08 $9,024,000.00
Disclosure

SEC source: 0001104659-20-061009 · a4.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,180,000

F1 · date: The transaction was effected by BioXcel Corporation. Effective April 23, 2020, BioXcel Corporation merged with and into BioXcel LLC.

F2 · ownership.nature: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and shareholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.

Read SEC document
January 02, 2020 Filed Apr 28, 2020 20:47 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $13.60 $0.00
Disclosure

SEC source: 0001104659-20-052445 · a4.xml · derivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-01-02

F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 2, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through the relevant vesting dates.

Read SEC document
April 01, 2019 Filed Feb 16, 2021 22:26 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 2

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By trust

Disclosed balance after: 1,000

F1 · ownership.nature: Shares held by The Sunanda Family Trust.

Read SEC document
April 01, 2019 Filed Feb 16, 2021 22:26 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 GiftCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0001104659-21-024409 · tm216714-1_4seq1.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Read SEC document
November 29, 2018 Filed Nov 30, 2018 21:17 UTC BioXcel Therapeutics, Inc. BTAI · Entity 8380 PurchaseCommon Stock 1,000 $4.92 $4,915.00
Disclosure

SEC source: 0001104659-18-070832 · a4.xml · nonDerivative · entry 1

Nandabalan Krishnan · CIK 0001733387 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · ownership.direct: By Krishnan Nandabalan and Suganthi Balasubramanian JTWROS

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.